78 related articles for article (PubMed ID: 21362794)
21. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
22. Tuberculosis and treatment with infliximab.
Myers A; Clark J; Foster H
N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859881
[No Abstract] [Full Text] [Related]
23. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis.
Sawar H; Espinoza LR; Gedalia A
J Rheumatol; 2004 Mar; 31(3):623; author reply 623-4. PubMed ID: 14994420
[No Abstract] [Full Text] [Related]
24. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
25. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Lovell DJ; Giannini EH; Reiff A; Jones OY; Schneider R; Olson JC; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Lange M; Finck BK; Burge DJ;
Arthritis Rheum; 2003 Jan; 48(1):218-26. PubMed ID: 12528122
[TBL] [Abstract][Full Text] [Related]
27. The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm.
Szyper-Kravitz M
Isr Med Assoc J; 2009 Oct; 11(10):633-4. PubMed ID: 20077953
[No Abstract] [Full Text] [Related]
28. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis.
Remesal A; DE Inocencio J; Merino R; Garcia-Consuegra J
J Rheumatol; 2010 Sep; 37(9):1970-1. PubMed ID: 20810527
[No Abstract] [Full Text] [Related]
29. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
30. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW
Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280
[TBL] [Abstract][Full Text] [Related]
31. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
Prince FH; Twilt M; Simon SC; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; ten Cate R; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 Jul; 68(7):1228-9. PubMed ID: 19525408
[No Abstract] [Full Text] [Related]
32. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
[TBL] [Abstract][Full Text] [Related]
33. The German etanercept registry for treatment of juvenile idiopathic arthritis.
Horneff G; Schmeling H; Biedermann T; Foeldvari I; Ganser G; Girschick HJ; Hospach T; Huppertz HI; Keitzer R; Küster RM; Michels H; Moebius D; Rogalski B; Thon A;
Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
[TBL] [Abstract][Full Text] [Related]
34. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.
Kietz DA; Pepmueller PH; Moore TL
J Rheumatol; 2001 Feb; 28(2):360-2. PubMed ID: 11246677
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
Borte S; Liebert UG; Borte M; Sack U
Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
[TBL] [Abstract][Full Text] [Related]
36. Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?
Eberhard BA; Ilowite NT
J Rheumatol; 2005 May; 32(5):763-5. PubMed ID: 15868605
[No Abstract] [Full Text] [Related]
37. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
38. Treatment of rheumatoid arthritis with etanercept.
Genovese MC; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
[TBL] [Abstract][Full Text] [Related]
39. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept.
Rajakulendran S; Deighton C
Rheumatology (Oxford); 2004 Dec; 43(12):1588-9. PubMed ID: 15564639
[No Abstract] [Full Text] [Related]
40. Etanercept-induced dermatitis in a patient with rheumatoid arthritis.
Lai-Cheong J; Warren R; Bucknall R; Parslew R
J Eur Acad Dermatol Venereol; 2006 May; 20(5):614-5. PubMed ID: 16684300
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
